NCT01579578 - Assess the Efficacy of AZD8931 in Combination With Paclitaxel Versus Paclitaxel Alone in Patients With Gastric Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

April 30, 2012

Primary Completion Date

March 31, 2013

Study Completion Date

March 31, 2013

Conditions

Metastatic, Gastric or Gastro-oesophageal Junction, Cancer

Interventions

DRUG

AZD8931

40 mg, oral dose twice daily

DRUG

Placebo

Placebo, oral dose twice daily

DRUG

Paclitaxel

IV once weekly for 3 weeks followed by a week off.

Trial Locations (15)

Research Site, Cologne

Research Site, Hamburg

Research Site, Chūōku

Research Site, Fukuoka

Research Site, Kawasaki-shi

Research Site, Matsuyama

Research Site, Sapporo

Research Site, Jeonju

Research Site, Seongnam-si

Research Site, Seoul

Research Site, Barcelona

Research Site, Madrid

Research Site, Valencia

Research Site, Taichung

Research Site, Taipei